Oncology providers frequently underestimate the incidence of chemotherapy-induced nausea and vomiting (CINV), and patients often are reluctant to report symptoms. Inadequate patient-provider communication is a significant barrier to optimal management of this debilitating toxicity.
Methods
The author reviews relevant published data and methods to optimize the clinical care of patients receiving chemotherapy with moderate-to-high emetogenic potential.
Results
Patient reticence plus physician expectations that patients will report symptoms accurately lead to lapses in communication and suboptimal clinical care.
Conclusions
Communication strategies should serve to encourage patients to share the responsibility for establishing goals of therapy and understanding the risks and benefits of their selected antiemetic regimen, thereby becoming active participants in their own cancer care.
References
1.
HeskethP.J.. Chemotherapy-induced nausea and vomiting.N Engl J Med.2008; 358(23): 2482–2494.
2.
KrisM.G., GrallaR.J., ClarkR.A.. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin.J Clin Oncol.1985; 3(10): 1379–1384.
3.
GrunbergS.M., DeusonR.R., MavrosP.. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics.Cancer.2004; 100(10): 2261–2268.
4.
De Jongh-GarciaC., PoliS., AnanthC.. Health care provider perception of nausea and vomiting and patients’ reported incidence: the Venezuela Emesis Registry.Support Care Cancer.2005; 13(6): 414–415. Abstract.
5.
Erazo ValleA., WisniewskiT., Figueroa VadilloJ.I.. Incidence of chemotherapy-induced nausea and vomiting in Mexico: healthcare provider predictions versus observed.Curr Med Res Opin.2006; 22(12): 2403–2410.
6.
LiauC.T., ChuN.M., LiuH.E.. Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians’ and nurses’ estimation vs patients’ reported outcomes.Support Care Cancer.2005; 13(5): 277–286.
7.
MolassiotisA., CoventryP.A., StrickerC.T.. Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC antiemesis tool.J Pain Symptom Manage.2007; 34(2): 148–159.
8.
MertensW.C., HigbyD.J., BrownD.. Improving the care of patients with regard to chemotherapy-induced nausea and emesis: the effect of feedback to clinicians on adherence to antiemetic prescribing guidelines.J Clin Oncol.2003; 21(7): 1373–1378.
9.
SalsmanJ., BeaumontJ., RosenbloomS.. Communicating about chemotherapy-induced nausea and vomiting: a comparison of patient and provider perspectives.Support Care Cancer.2009; 17(1): 884. Abstract.
10.
CohenL., de MoorC.A., EisenbergP.. Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings.Support Care Cancer.2007; 15(5): 497–503.
11.
MolassiotisA., SaundersM.P., ValleJ.. A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre.Support Care Cancer.2008; 16(2): 201–208.
12.
StorrM.A., SharkeyK.A.. The endocannabinoid system and gut-brain signalling.Curr Opin Pharmacol.2007; 7(6): 575–582.
NavariR.M., BrennerM.C.. Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial.Support Care Cancer.2010; 18(8): 951–956.
15.
BaschE., PrestrudA.A., HeskethP.J.. Antiemetics: American Society of Clinical Oncology clinical practice guideline update.J Clin Oncol.2011; 29(31): 4189–4198.
16.
EttingerD.S., ArmstrongD.K., BarbourS.. Antiemesis: clinical practice guidelines in oncology.J Natl Compr Canc Netw.2009; 7(5): 572–595.
17.
RoilaF., HerrstedtJ., AaproM.. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.Ann Oncol.2010; 21(suppl 5): v232–v243.
18.
GrunbergS.M., WarrD., GrallaR.J.. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—state of the art.Support Care Cancer.2011; 19(suppl 1): S43–S47.
19.
GrallaR., LichinitserM., Van Der VegtS.. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.Ann Oncol.2003; 14(10): 1570–1577.
20.
EisenbergP., Figueroa-VadilloJ., ZamoraR.. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.Cancer.2003; 98(11): 2473–2482.
21.
GrunbergS., ChuaD., MaruA.. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol—EASE.J Clin Oncol.2011; 29(11): 1495–1501.
22.
RoscoeJ.A., MorrowG.R., AaproM.S.. Anticipatory nausea and vomiting.Support Care Cancer.2011; 19(10): 1533–1538.
23.
KaiserR., SezerO., PapiesA.. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes.J Clin Oncol.2002; 20(12): 2805–2811.
24.
TremblayP.B., KaiserR., SezerO.. Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients.J Clin Oncol.2003; 21(11): 2147–2155.
25.
HassanB.A., YusoffZ.B.. Genetic polymorphisms in the three malaysian races effect granisetron clinical antiemetic actions in breast cancer patients receiving chemotherapy.Asian Pac J Cancer Prev.2011; 12(1): 185–191.
26.
CoatesA., AbrahamS., KayeS.B.. On the receiving end—patient perception of the side-effects of cancer chemotherapy.Eur J Cancer Clin Oncol.1983; 19(2): 203–208.
27.
GrunbergS.M., BoutinN., IrelandA.. Impact of nausea/vomiting on quality of life as a visual analogue scale-derived utility score.Support Care Cancer.1996; 4(6): 435–439.
28.
SunC.C., BodurkaD.C., DonatoM.L.. Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time?Gynecol Oncol.2002; 87(1): 118–128.
29.
IOM (Institute of Medicine).Patient-Centered Cancer Treatment Planning: Improving the Quality of Oncology Care: Workshop Summary.Washington, DC: The National Academies Press; 2011.
30.
BerryD.L., BlumensteinB.A., HalpennyB.. Enhancing patient-provider communication with the electronic self-report assessment for cancer: a randomized trial.J Clin Oncol.2011; 29(8): 1029–1035.
31.
GivenC.W., SikorskiiA., TamkusD.. Managing symptoms among patients with breast cancer during chemotherapy: results of a two-arm behavioral trial.J Clin Oncol.2008; 26(36): 5855–5862.
